摘要
目的比较地特胰岛素与门冬胰岛素30联合二甲双胍治疗2型糖尿病的疗效和安全性。方法选择医院2015年7月至2017年7月医院收治的2型糖尿病患者98例,按随机数字表法分为两组,各49例。对照组采用门冬胰岛素30联合二甲双胍治疗,观察组采用地特胰岛素联合二甲双胍治疗。结果治疗后,两组患者空腹血糖、餐后2 h血糖、糖化血红蛋白水平均低于治疗前(P <0. 05),但组间差异无统计学意义(P> 0. 05);观察组患者体质量、胰岛素用量、血糖达标时间,以及各不良反应发生率与对照组相比,差异无统计学意义(P> 0. 05)。结论地特胰岛素联合二甲双胍与门冬胰岛素30联合二甲双胍治疗2型糖尿病均具有显著疗效且疗效相当,可有效控制血糖水平,缩短血糖达标时间,且低血糖发生率低,临床可根据实际情况选择治疗方案。
Objective To compare the efficacy and safety of Insulin Detemir or Insulin Aspart 30 Injection combined with metformin in the treatment of type 2 diabetes mellitus（T2DM）. Methods Totally 98 patients with T2DM admitted to our hospital from July 2015 to July 2017 were divided into two groups according to the random number table method, 49 cases in each group. The control group was treated with Insulin Aspart 30 Injection combined with metformin, while the observation group was treated with Insulin Detemir combined with metformin. Results After treatment, the levels of FBG, 2 hPG and HbAlc in the two groups were lower than those before treatment, but there was no significant difference between the two groups（P 〉 0.05）. There was no significant difference in the body weight, insulin dosage, time of blood glycose control, incidence rate of adverse reactions between the two groups（P 〉 0.05）. Conclusion Both Insulin Detemir combined with metformin and Insulin Aspart 30 Injection combined with metformin in the treatment of T2DM have significant effects and the effects are similar. They can effectively control the blood glucose level, shorten the time of glycemic control with low in- cidence of bypoglycemia. Clinical treatment options can be chosen according to the actual situation.
作者
马齐芳
Ma Qifang(Zhongda Hospital Affiliated to Southeast University〈 Jiangbei〉,Nanjing Dachang Hospital,Nanjing,Jiangsu,China 210044)
出处
《中国药业》
CAS
2018年第22期59-61,共3页
China Pharmaceuticals
关键词
地特胰岛素
二甲双胍
门冬胰岛素30
2型糖尿病
疗效
安全性
Insulin Detemir
metformin
Insulin Aspart 30 Injection
type 2 diabetes mellitus
curative effect
safety
作者简介
马齐芳，女，大学本科，主治医师，研究方向为内分泌科疾病的诊治，（电子信箱）1092597430@qq．com。
